[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Duke University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":653},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,252,0,25,[9,50,107,130,143,169,193,221,249,270,294,318,343,369,392,422,439,466,490,514,546,566,592,615,636],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100053769","phase-4-inclisiran-versus-placebo-for-the-prevention-of-major-adverse-cardiovascular-and-limb-events-in-patients-undergoing-percutaneous-coronary-intervention-or-peripheral-endovascular-intervention-100053769",false,"NCT06909565","Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention","Evaluation of Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention (V-INTERVENTION)","V-INTERVENTION","Inclusion Criteria:\n\n* Signed informed consent must be obtained prior to participation in the study.\n* Males or females ≥ 18 years of age\n* Within 14 days of a successful percutaneous coronary intervention (PCI) or peripheral endovascular intervention (PVI) for symptomatic CAD or lower extremity PAD\n* Patients undergoing planned staged interventions are eligible for randomization only after the last planned intervention\n\nExclusion Criteria:\n\n* Planned future PCI or PVI\n* Current or planned use of an open-label PCSK9 inhibitor during the study\n* Any prior treatment with inclisiran\n* Active or planned participation in another clinical study involving investigational drugs or devices during the study\n* Any serious liver disease, metabolic disease, neoplasm, end-stage kidney disease, or other condition in the opinion of the investigator that would inhibit trial participation or confound trial results\n* Any other reason why, in the opinion of the investigator, the participant would not be suitable for study participation including safety considerations and the ability to adhere to protocol activities\n* Patients taking prohibited therapies as listed in Section 6.6.3\n* Pregnant or breast-feeding women","ALL","18 Years",{"count":21,"type":22},6000,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","V-INTERVENTION will evaluate the effectiveness of inclisiran in preventing major cardiovascular and limb events in patients receiving percutaneous coronary or peripheral arterial revascularization. Inclisiran is a subcutaneous, twice-yearly injection that is FDA-approved as an adjunct with statin therapy and on the market to lower LDL-C in high-risk populations.",[28,29],"Percutaneous Coronary Intervention","Peripheral Endovascular Intervention",[31,32,33,34,35,28,36],"inclisiran","Coronary Artery Disease","hypercholesterolemia","Cardiovascular Disease","Percutaneous Endovascular Intervention","PCSK9","RECRUITING","2026-07-10",{"date":40,"type":41},"2026-07-13","ACTUAL",{"date":43,"type":41},"2025-07-23",{"date":45,"type":22},"2029-12",{"name":47,"class":48},"Duke University","OTHER",111,{"id":51,"slug":52,"hasResults":12,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":58,"sex":18,"minAge":19,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":23,"phases":62,"briefSummary":64,"conditions":65,"keywords":67,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":100,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},"100054313","transcranial-magnetic-brain-stimulation-to-reduce-cannabis-use-in-heavy-cannabis-users-100054313","NCT05401929","Transcranial Magnetic Brain Stimulation to Reduce Cannabis Use in Heavy Cannabis Users","Imaging the Effects of Intermittent Thetaburst Stimulation on Cannabis Self-Administration in Heavy Cannabis Users","iCURE","Inclusion Criteria:\n\n* Males\u002Fnon-pregnant females, 18-65 years old\n* Current cannabis user\n* Able to perform all study procedures\n\nExclusion Criteria:\n\n* Regular use of other illicit drugs\n* If medical history, physical and psychiatric examination, or laboratory tests performed during the screening process reveal any significant illness that the study physician deems contraindicated for study participation",true,"65 Years",{"count":61,"type":22},50,[63],"NA","The growing legalization of cannabis across the U.S. is associated with increases in cannabis use, and accordingly, an increase in the number of individuals with cannabis use problems, including cannabis use disorder (CUD). While there are several medications being investigated as treatment options for CUD, none have been FDA-approved, and there is limited efficacy of traditional behavioral therapy approaches for this population. Consequently, there is a pressing need for the development of new treatments, including approaches that specifically target the brain areas associated with problematic cannabis use behaviors. Elevated attention to drug cues is one of the primary causes of relapse in heavy cannabis users. Preliminary data suggests that repetitive transcranial magnetic stimulation (rTMS), a non-invasive form of brain stimulation, may be a novel brain-based tool to decrease heightened attention to drug cues in people with CUD. Building on prior data, the primary goal of this study is to evaluate the feasibility and effectiveness of TMS as a tool to decrease attention to drug cues and reduce cannabis use.\n\nIn this study, fifty (50) treatment-seeking, near-daily cannabis users will be recruited to receive either active or sham (placebo) repetitive TMS (rTMS). Participants will complete a total of 25 treatment sessions, delivered as five sessions per day across five days, with sessions flexibly scheduled over a two-week period. Measures of cannabis use and brain activity will be collected before and after treatment using real-time self-report assessments and functional magnetic resonance imaging (fMRI), respectively. Specifically, cannabis use will be assessed in participants' everyday environments using brief text-message surveys during a two-week baseline period, the two-week treatment period, and a four-week follow-up period.\n\nThe study aims to determine whether active rTMS reduces brain activity in response to cannabis cues, decreases automatic attention to cannabis cues, and leads to meaningful reductions in cannabis use compared to sham treatment.",[66],"Cannabis",[68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99],"cannabis","transcranial magnetic stimulation","repetitive transcranial magnetic stimulation","intermittent theta burst stimulation","functional magnetic resonance imaging","functional neuroimaging","functional brain imaging","marijuana","cannabis smoking","marijuana smoking","recreational marijuana use","stroop task","attentional bias","drug cue reactivity","intervention","treatment","double blind","sham","sham controlled","ecological momentary assessment","randomized controlled clinical trials","randomized clinical trials","neuronavigation","personalized cortical targeting","biomarker development","brain mapping","neuroendophenotypes","neurobiomarkers","accelerated","functional connectivity","network","fmri",{"date":40,"type":41},{"date":102,"type":41},"2022-06-01",{"date":104,"type":22},"2029-07",{"name":47,"class":48},1,{"id":108,"slug":109,"hasResults":12,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":58,"sex":18,"minAge":114,"maxAge":4,"enrollmentInfo":115,"targetDuration":117,"studyType":118,"phases":4,"briefSummary":119,"conditions":120,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":106},"100054163","lung-health-and-the-microbiome-among-adults-in-botswana-the-go-hema-cohort-100054163","NCT07699614","Lung Health and the Microbiome Among Adults in Botswana: the Go-hema Cohort","Determinants of Lung Health Among Batswana Adults With and Without HIV: the Go-Hema Study","Inclusion Criteria:\n\n* Adults 35 years of age or older\n* In case at a clinic in Botswana\n* Documented HIV status\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Respiratory infection in the prior 4 weeks\n* Active pulmonary tuberculosis\n* Inability to perform spirometry including eye, abdominal, or\n* Thoracic surgery or myocardial infarction in the prior 6 weeks\n* Pregnancy","35 Years",{"count":116,"type":22},900,"4 Months","OBSERVATIONAL","Chronic respiratory diseases like chronic obstructive pulmonary disease (COPD) are responsible for millions of deaths each year, the majority of which occur in low- and middle-income countries (LMICs). LMICs also have high rates of abnormal lung function, including restrictive spirometric pattern (RSP), which can precede the development of chronic respiratory diseases and is associated with all-cause mortality. Additionally, LMICs in sub-Saharan Africa are home to the majority of the world's population of people with HIV (PWH). HIV increases the risk of COPD and COPD associated mortality, but the mechanisms underlying this risk are incompletely understood.",[121,122],"Obstructive Pulmonary Disease","Restrictive Pulmonary Disease","2026-07-08",{"date":40,"type":41},{"date":126,"type":41},"2024-12-01",{"date":128,"type":22},"2030-12-20",{"name":47,"class":48},{"id":131,"slug":4,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":132,"targetDuration":4,"studyType":23,"phases":133,"briefSummary":26,"conditions":134,"keywords":135,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":140,"leadSponsor":141,"locationsCount":142},"100585991",{"count":21,"type":22},[25],[28,29],[31,32,33,34,35,28,36],"2026-07-01",{"date":138,"type":41},"2026-07-02",{"date":43,"type":41},{"date":45,"type":22},{"name":47,"class":48},109,{"id":144,"slug":145,"hasResults":12,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":149,"eligibilityCriteria":150,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":151,"targetDuration":4,"studyType":23,"phases":152,"briefSummary":153,"conditions":154,"keywords":157,"overallStatus":161,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":106},"100642215","lattice-radiotherapy-for-adults-with-large-tumors-100642215","NCT07647679","Lattice Radiotherapy for Adults With Large Tumors","Pilot Study of Lattice Radiotherapy in Adults With Large Tumors","LRT","Inclusion Criteria:\n\n* Histologically or cytologically confirmed malignancy diagnosis\n* Radiographic evidence of large extracranial tumor (≥ 4.5 cm)\n* Patients with primary or metastatic extracranial tumors may be included\n* Planned to undergo palliative radiation treatment\n* Life expectancy of at least 3 months\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 3\n* Patient must sign study-specific informed consent\n\nExclusion Criteria:\n\n* Primary lesion with radiosensitive histology (i.e. germ cell tumors, lymphoma, leukemia, and multiple myeloma)\n* Prior radiation treatment that overlaps with any planned site of protocol radiotherapy that would preclude further palliative RT.\n* Receiving concurrent cytotoxic cancer therapy regimens or Vascular Endothelial Growth Factor (VEGF) inhibitor that would overlap with LRT administration. Cytotoxic chemotherapy, targeted therapies, small molecule inhibitors, or sVEGF inhibitors prior to radiation treatment or planned after radiation delivery are allowed at the discretion of the treating radiation oncologist.",{"count":7,"type":22},[63],"The purpose of this study is to ask whether using a specialized radiation therapy technique called Lattice Radiation Therapy (LRT) can shrink large tumors when given with palliative radiation therapy. The primary questions are:\n\n* if LRT is safe and does not worsen existing side effects or cause new side effects\n* if adding LRT to standard radiation therapy can improve tumor shrinkage. Participants will have one additional radiation treatment (LRT) prior to starting palliative radiation and then their progress will be followed for one year.",[155,156],"Large Tumor","Palliative Radiotherapy",[158,159,160],"palliative radiation therapy","large tumor","lattice radiation therapy (LRT)","NOT_YET_RECRUITING","2026-06-29",{"date":136,"type":41},{"date":165,"type":22},"2026-08-01",{"date":167,"type":22},"2030-08",{"name":47,"class":48},{"id":170,"slug":171,"hasResults":12,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":4,"eligibilityCriteria":175,"healthyVolunteers":12,"sex":176,"minAge":19,"maxAge":4,"enrollmentInfo":177,"targetDuration":4,"studyType":23,"phases":179,"briefSummary":180,"conditions":181,"keywords":185,"overallStatus":161,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":186,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":192},"100644558","orasis-in-breast-reconstruction-100644558","NCT07670754","ORASIS in Breast Reconstruction","ORASIS and Microsurgical Anastomosis Outcomes in DIEP Flap Breast Reconstruction: A Crossover Randomized Controlled Trial","Inclusion:\n\n* Female Deep Inferior Epigastric Perforator (DIEP) flap breast reconstruction patients who have received a prior mastectomy (either unilateral or bilateral) on the breast undergoing reconstruction\n* Patients who received mastectomies for oncologic or prophylactic indications\n* Patients receiving either immediate or delayed DIEP flap breast reconstruction\n* Age 18 or older at the time of patient consent and DIEP flap surgery\n\nExclusion:\n\n* History of any prior tissue expander placement or breast reconstruction on the breast undergoing DIEP flap reconstruction\n* Patients receiving DIEP flap breast reconstruction for indications other than oncologic or prophylactic post-mastectomy breast reconstruction\n* Under the age of 18 at the time of patient consent or DIEP flap surgery","FEMALE",{"count":178,"type":22},30,[63],"The purpose of this study is to assess the use of ORASIS during microsurgical anastomosis formation in Deep Inferior Epigastric Perforator (DIEP) flap breast reconstruction and its potential effects on surgical precision, surgeon efficiency, and anastomosis outcomes. The investigators hypothesize that the use of ORASIS will decrease the amount of time needed to perform microsurgical anastomoses, reduce interruptions for irrigation and suction, and increase the quality of anastomoses in DIEP flap breast reconstruction.",[182,183,184],"DIEP Flap","Breast Reconstruction","Breast Cancer",[182,183,184],{"date":136,"type":41},{"date":188,"type":22},"2026-12",{"date":190,"type":22},"2027-12",{"name":47,"class":48},2,{"id":194,"slug":195,"hasResults":12,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":199,"eligibilityCriteria":200,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":201,"targetDuration":4,"studyType":23,"phases":203,"briefSummary":205,"conditions":206,"keywords":208,"overallStatus":161,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":220,"locationsCount":106},"100645312","phase-2-phosphate-in-acute-pancreatitis-100645312","NCT07681050","Phosphate in Acute Pancreatitis","Phosphate in Acute Pancreatitis (PPP)","PPP","Inclusion Criteria:\n\n* Age 18 years or older\n* Presenting to the emergency department (ED) with acute pancreatitis meeting 2 or more characteristics of: (1) typical, persistent, severe upper abdominal pain, (2) lipase or amylase levels at least three times greater than the upper limit of normal, and\u002For (3) characteristic findings on abdominal imaging)\n* Trial treatment can be initiated within 24 hours of hospital admission\n* Consent can be obtained from the patient or their legal representative\n\nExclusion Criteria:\n\nContraindications to injectable phosphate including:\n\n* Hyperkalemia\n* Hypercalcemia or significant hypocalcemia\n* Severe renal impairment (eGFR \\\u003C30 mL\u002Fmin\u002F1.73m2) or end-stage renal disease",{"count":202,"type":22},100,[204],"PHASE2","The goal of this study is to learn if phosphate administration works to treat acute pancreatitis in adults presenting to the emergency department at Duke University Hospital. The main questions it aims to answer are:\n\n* Does having low phosphate levels increase the risk of acute pancreatitis and can giving phosphate through an IV make the illness less severe?\n* Is phosphate therapy practical to use, and what is the appropriate dose?\n* Is this study achievable, and how can the results help design a future randomized controlled trial to assess safety and effectiveness?\n\nParticipants will:\n\n* Receive standard of care or intravenous (IV) phosphate during their hospital stay\n* Have blood samples collected during admission to monitor phosphorus levels\n* Complete follow-up assessments after hospital admission to evaluate how severe the illness is and the effects of phosphate supplementation",[207],"Pancreatitis",[209,207,210,211,212,213,214],"Pancreas","Phosphate","Hypophosphatemia","Hyperphosphatemia","Sodium Phosphate","Potassium Phosphate","2026-06-26",{"date":138,"type":41},{"date":218,"type":22},"2026-07",{"date":104,"type":22},{"name":47,"class":48},{"id":222,"slug":223,"hasResults":12,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":227,"eligibilityCriteria":228,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":229,"targetDuration":4,"studyType":23,"phases":231,"briefSummary":232,"conditions":233,"keywords":236,"overallStatus":161,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":248,"locationsCount":106},"100645128","comparing-strategies-to-improve-non-pharmacologic-pain-relief-for-adults-with-back-pain-using-the-education-navigated-care-and-supported-self-management-pain-care-program-100645128","NCT07679178","Comparing Strategies to Improve Non-Pharmacologic Pain Relief for Adults With Back Pain Using the Education, Navigated Care, and Supported Self-management Pain Care Program","Comparing Strategies to Improve Non-Pharmacologic Pain Relief for Adults With Back Pain (The ENCompaSS Trial)","ENCompaSS","Inclusion Criteria:\n\n* Be age 18 years old or older\n* Have a VA outpatient clinic visit for low back pain within the previous 30 days\n* Be enrolled in a participating primary care clinic\n* Have high impact chronic pain per Graded Chronic Pain Scale (most days or every day on first 2 items)\n* Valid telephone access\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Are currently hospitalized or residing in a nursing home\n* Have cognitive impairment or lack of decision-making capacity\n* Have a serious mental illness (e.g., schizophrenia, bipolar disorder, recent psychiatric hospitalization, high risk suicide flag)\n* Are unable to communicate by telephone or have no telephone access",{"count":230,"type":22},530,[63],"The goal of this clinical trial is to help Veterans manage high-impact chronic low back pain. The trial will use a program, ENCompaSS (Education, Navigated Care, and Supported Self-Management) designed to reduce pain more than usual care alone. Researchers will assess a) the impact of ENCompaSS, b) identify which Veterans benefit the most, and c) how this program can be delivered more broadly in other clinics and health systems.\n\nWhat Will Happen:\n\nVeterans in this clinical trial will be randomly placed into one of two groups.\n\nENCompaSS group (intervention):\n\n* Have at least three phone calls with a trained clinician over about 12 weeks\n* Watch short online videos about managing pain\n* Complete surveys before the study and again at 2, 4, 6, and 12 months\n\nUsual care group:\n\n* Will continue with regular care\n* Complete the same surveys at the same time points",[234,235],"Chronic Low-back Pain (cLBP)","High-Impact Chronic Pain (HICP)",[237,238,239,240,241],"Veterans","Low Back Pain","Clinical Pathway","Pain Management","Non-Pharmacologic","2026-06-25",{"date":136,"type":41},{"date":245,"type":22},"2026-10",{"date":247,"type":22},"2029-07-31",{"name":47,"class":48},{"id":250,"slug":251,"hasResults":12,"nctId":252,"briefTitle":253,"officialTitle":253,"acronym":4,"eligibilityCriteria":254,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":255,"enrollmentInfo":256,"targetDuration":4,"studyType":23,"phases":258,"briefSummary":259,"conditions":260,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":106},"100560328","coping-skills-training-for-symptom-management-and-daily-steps-step-up-100560328","NCT06575712","Coping Skills Training for Symptom Management and Daily Steps (Step Up)","Inclusion Criteria:\n\n* receipt of an autologous (auto) HCT or CAR-T cell therapy due to a hematologic malignancy, such as a diagnosis of leukemia, lymphoma, multiple myeloma\n* age \\>18\n* self-reported fatigue, pain, and psychological distress (confirmed at recruitment) - minimum two of three symptoms reported at \\>3 on 0-10 scale\n* life expectancy \\> 12 months\n\nExclusion Criteria:\n\n* cognitive impairment (e.g., dementia) recorded in the chart or suspected by provider\n* metastases to the brain\n* presence of a severe psychiatric condition (e.g., psychotic disorder) that would contraindicate safe participation as indicated by the medical chart, treating oncologist, or interactions with the medical\u002Fstudy staff\n* inability to converse in English","99 Years",{"count":257,"type":22},177,[63],"The aim of this study is to test the efficacy of a hybrid in-person and mHealth coping skills training and activity coaching intervention (Step Up), to enable HCT patients to effectively cope with symptoms (pain, fatigue, and stress) to improve their ability to engage in physical activity that can improve physical disability.",[261,262],"Hematopoietic Stem Cell Transplant","CAR-T Cell Therapy","2026-06-24",{"date":242,"type":41},{"date":266,"type":41},"2025-04-21",{"date":268,"type":22},"2029-07-15",{"name":47,"class":48},{"id":271,"slug":272,"hasResults":12,"nctId":273,"briefTitle":274,"officialTitle":275,"acronym":4,"eligibilityCriteria":276,"healthyVolunteers":58,"sex":18,"minAge":277,"maxAge":278,"enrollmentInfo":279,"targetDuration":4,"studyType":23,"phases":281,"briefSummary":282,"conditions":283,"keywords":285,"overallStatus":161,"whyStopped":4,"lastUpdateSubmitDate":287,"lastUpdatePostDateStruct":288,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":293,"locationsCount":4},"100632871","dosing-and-deployment-trial-a-home-based-optokinetic-treatment-100632871","NCT07519317","Dosing and Deployment Trial: A Home-based Optokinetic Treatment","Dosing and Deployment Trial: A Home-based Optokinetic Treatment for Ipsilesional Gaze Deviation","Inclusion Criteria for stroke group:\n\n1. first and unilateral right brain damage stroke, confirmed by medical records,\n2. time post stroke \\>6 months,\n3. moderate to severe SN, classified using the Catherine Bergego Scale (CBS) via the Kessler Foundation Neglect Assessment Process (KF-NAP),\n4. over age of 60 years, and\n5. IGD noted either on the KF-NAP or neuroimaging from medical records.\n\nExclusion Criteria for stroke group:\n\n1. history of multiple strokes or neurological incidents (e.g., traumatic brain injury, seizures, or brain tumor),\n2. unable to communicate through spoken English, screened using the Aphasia Rapid Test (ART), as instructions for treatment and assessment tasks will be provided verbally in English,\n3. cognitive impairment as defined by the Blind-MoCA,\n4. dependent in mobility- walking or wheelchair via medial chart,\n5. legally blind per medical chart,\n6. home located out of a 50-mile radius from Duke University, making it too costly for the frequent home visits, and\n7. no IGD present.\n\nInclusion Criteria for caregiver group:\n\n1. a current care partner (defined as someone providing care and assistance) of a stroke survivor living with SN,\n2. English speaker,\n3. the stroke survivor they are caring for has been enrolled into the study.\n\nExclusion Criteria for caregiver group:\n\n1. not a care partner currently,\n2. can't speak English,\n3. the stroke survivor didn't consent","60 Years","110 Years",{"count":280,"type":22},90,[63],"Several interventions exist for remediation of spatial neglect, but they have mixed evidence. Optokinetic stimulation is a bottom-up intervention; in other words, it is a stimulus-driven process, with Level A (strongest) evidence, and is recommended in clinical practice guidelines such as the American Heart Association's stroke guidelines. The studies currently published all use varing doses (number of sessions a week), did not assess the impact on mobility and risk of falls, and have not been implemented in the home setting. It is imperative to understand how to successfully implement this intervention at home, and learn how it will impact mobility in order to better support a large population of individuals living with chronic spatial neglect and who face barriers to accessing care because they require caregiver support to leave the home. This will be done using both qualitative and quantitative methods.",[284],"Spatial Neglect",[286],"spatial neglect; optokinetic stimulation; stroke","2026-06-22",{"date":242,"type":41},{"date":290,"type":22},"2027-01-04",{"date":292,"type":22},"2028-06-16",{"name":47,"class":48},{"id":295,"slug":296,"hasResults":12,"nctId":297,"briefTitle":298,"officialTitle":299,"acronym":4,"eligibilityCriteria":300,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":301,"enrollmentInfo":302,"targetDuration":4,"studyType":23,"phases":304,"briefSummary":305,"conditions":306,"keywords":308,"overallStatus":161,"whyStopped":4,"lastUpdateSubmitDate":312,"lastUpdatePostDateStruct":313,"startDateStruct":314,"completionDateStruct":315,"leadSponsor":317,"locationsCount":106},"100610473","phase-4-esp-blocks-for-posterior-spinal-fusion-100610473","NCT07228039","ESP Blocks for Posterior Spinal Fusion","A Double-Blind Prospective RCT Assessment of ESP Blocks for Analgesia Following Posterior Spinal Fusion","Inclusion Criteria\n\n* English speaking\n* Age 18-75\n* ASA physical status 1-3\n* Undergoing elective cervical or lumbar posterior spinal fusion (≤3 levels)\n\nExclusion Criteria\n\n* Age \\\u003C18 or \\>75\n* ASA IV or V\n* Non-English speaking\n* BMI \\>40\n* Opioid dependence\n* Chronic pain\n* Anticoagulation or coagulopathy\n* Injection site infection\n* Hepatic or renal insufficiency\n* Allergy to study drugs\n* Pregnancy\n* Inability to communicate with investigators","75 Years",{"count":303,"type":22},75,[25],"This prospective randomized double-blind study evaluates the efficacy of erector spinae plane (ESP) blocks on postoperative pain in patients undergoing cervical or lumbar posterior spinal fusion. Patients will receive either 0.5% bupivacaine plus liposomal bupivacaine or 0.5% plain bupivacaine. Outcomes include opioid consumption over 72 hours, pain scores, length of stay, and time to ambulation.",[307],"Postoperative Pain",[309,310,311],"ESP Block","Spinal Fusion","Multimodal Analgesia","2026-06-17",{"date":287,"type":41},{"date":218,"type":22},{"date":316,"type":22},"2028-01",{"name":47,"class":48},{"id":319,"slug":320,"hasResults":12,"nctId":321,"briefTitle":322,"officialTitle":323,"acronym":4,"eligibilityCriteria":324,"healthyVolunteers":58,"sex":18,"minAge":19,"maxAge":325,"enrollmentInfo":326,"targetDuration":4,"studyType":23,"phases":328,"briefSummary":329,"conditions":330,"keywords":332,"overallStatus":161,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":337,"startDateStruct":338,"completionDateStruct":340,"leadSponsor":342,"locationsCount":4},"100642200","calibre-vs-cosmed-100642200","NCT07596108","Calibre vs. COSMED","Correlation of Cardiopulmonary Exercise Testing (CPET) VO2 Max Parameters Between the Calibre Device and COSMED Metabolic Cart","Inclusion Criteria:\n\n* Age 18-55\n* Able to speak English\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Acute myocardial infarction\n* Unstable angina\n* Syncope\n* Uncontrolled asthma\n* Arterial desaturation at rest on room air \\\u003C85%\n* Severe untreated arterial hypertension at rest (\\>200 mm Hg systolic, \\>120 mm Hg diastolic)\n* Significant pulmonary hypertension\n* Active thrombosis of the lower extremity, unless treated for at least 2 weeks prior to participation.\n* Within 2 weeks of acute symptomatic pulmonary embolus\n* Considered inappropriate to participate by Principal Investigator\n* Previously experienced a heart attack\n* Pregnancy","55 Years",{"count":327,"type":22},40,[63],"This study evaluates agreement between the Calibre device and the COSMED Quark CPET system for measurement of cardiorespiratory fitness parameters during maximal exercise testing in adults aged 18-55 years.",[331],"Cardiorespiratory Fitness",[333,334,335],"Cardiopulmonary Exercise Testing","VO2 Max","Exercise Physiology","2026-06-16",{"date":312,"type":41},{"date":339,"type":22},"2026-09",{"date":341,"type":22},"2027-07",{"name":47,"class":48},{"id":344,"slug":345,"hasResults":12,"nctId":346,"briefTitle":347,"officialTitle":348,"acronym":349,"eligibilityCriteria":350,"healthyVolunteers":58,"sex":18,"minAge":19,"maxAge":351,"enrollmentInfo":352,"targetDuration":4,"studyType":23,"phases":354,"briefSummary":355,"conditions":356,"keywords":359,"overallStatus":161,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":364,"startDateStruct":365,"completionDateStruct":366,"leadSponsor":368,"locationsCount":106},"100625950","phase-4-spark-study---sympathetic-periarterial-radial-block-in-healthy-volunteers-100625950","NCT07429292","SPARK Study - Sympathetic Periarterial Radial Block in Healthy Volunteers","SPARK Study - Sympathetic PeriArterial Radial blocK Study","SPARK","Inclusion Criteria:\n\n* Age 18-50 years\n* ASA physical status I-II\n* Able to understand and provide informed consent\n* Able to comply with study procedures and follow-up\n* Two hands with 5 intact digits and no significant upper extremity injury\n\nExclusion Criteria:\n\n* Allergy to lidocaine or similar anesthetics\n* Allergy to adhesives or ultrasound gel\n* Neuromuscular, autonomic, or major vascular disorders affecting upper extremities\n* Peripheral neuropathy\n* Raynaud's phenomenon or digital ischemia\n* Coagulopathy or anticoagulation\n* Active skin infection near block site\n* Pregnancy\n* BMI \\> 35 kg\u002Fm²\n* Inability to tolerate cold exposure\n* Any condition interfering with study conduct","50 Years",{"count":353,"type":22},20,[25],"The SPARK Study evaluates changes in peripheral sympathetic vasomotor activity following a targeted, ultrasound-guided periarterial sympathetic block of the distal radial artery in healthy volunteers. Autonomic reactivity will be assessed before and after the block using digit-specific pulse-amplitude index and infrared thermography during standardized cold pressor testing.",[357,358],"Healthy Volunteers","Sympathetic Activity",[360,361,362,363],"Sympathetic Block","Radial Artery","Cold Pressor Test","Periarterial block",{"date":312,"type":41},{"date":339,"type":22},{"date":367,"type":22},"2027-04",{"name":47,"class":48},{"id":370,"slug":371,"hasResults":12,"nctId":372,"briefTitle":373,"officialTitle":374,"acronym":375,"eligibilityCriteria":376,"healthyVolunteers":58,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":377,"targetDuration":4,"studyType":23,"phases":378,"briefSummary":379,"conditions":380,"keywords":383,"overallStatus":161,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":388,"startDateStruct":389,"completionDateStruct":390,"leadSponsor":391,"locationsCount":4},"100598188","phase-2-rectus-sheath-trial-100598188","NCT07068243","REctus Sheath Trial","Transverse Versus Longitudinal Approaches for Rectus Sheath Block: a Randomized Controlled Trial in Healthy Volunteers","REST","Inclusion criteria:\n\n1. Ability to provide written informed consent\n2. Ability and willingness to comply with the study procedures and duration requirements\n3. ASA physical status 1 or 2\n4. Age ≥ 18 years\n5. Weight \\> 60kg\n\nExclusion criteria:\n\n1. BMI \\> 40kg.m-2\n2. Use of analgesics within 24 hours before the procedure\n3. History of abdominal trauma or surgery\n4. Abdominal deformities or abnormalities that may prevent proper block performance\n5. Abdominal tattoos in the supraumbilical area\n6. Systemic neuromuscular disease\n7. Contraindications to regional anesthesia (e.g., infection, allergy)\n8. Structures are unable to be visualized by ultrasound\n9. Pregnancy\n10. Other known health conditions that would affect the participant's ability to successfully complete the study",{"count":7,"type":22},[204],"Regional anesthesia techniques (or nerve blocks) are used to provide sensory blockade over the abdominal wall. The most established technique is thoracic epidural. This provides bilateral spread but is also associated with neuraxial complications, which has led to a decrease in clinical usage. The rectus sheath block (RSB) is an established regional anesthesia technique used to provide somatic analgesia to the midline anterior abdominal wall by depositing local anesthetic in the posterior rectus sheath, thereby targeting the terminal anterior branches of the lower thoracic intercostal nerves. The conventional approach involves placing the ultrasound (US) probe transversely across the rectus abdominis muscle and advancing the needle in-plane either lateral-to-medial or medial-to-lateral. While this technique achieves spread within the sheath, the cephalocaudal distribution of local anesthetic may be suboptimal, potentially limiting the extent of dermatomal coverage. A longitudinal probe orientation, with needle insertion from cephalad to caudad, may theoretically facilitate a more extensive cranio-caudal spread by aligning the injection axis with the anatomical fascial plane of the posterior rectus sheath. However, the relative efficacy of these two approaches has not been investigated in a controlled, comparative setting. Thus, this randomized, single-blinded trial aims to evaluate the dermatomal sensory distribution and ultrasound-assessed local anesthetic spread achieved by the transverse versus longitudinal in-plane approaches to ultrasound-guided RSB in healthy adult volunteers. To compare the dermatomal sensory block distribution, investigators will use dermatomal mapping with pinprick, and cold.",[381,382],"Acute Pain","Postoperative Pain, Acute",[384,385,386,387],"Rectus Sheath Block","Abdominal Block","Fascial Plane Block","RSB",{"date":312,"type":41},{"date":339,"type":22},{"date":367,"type":22},{"name":47,"class":48},{"id":393,"slug":394,"hasResults":12,"nctId":395,"briefTitle":396,"officialTitle":397,"acronym":398,"eligibilityCriteria":399,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":400,"targetDuration":4,"studyType":23,"phases":402,"briefSummary":403,"conditions":404,"keywords":408,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":414,"lastUpdatePostDateStruct":415,"startDateStruct":416,"completionDateStruct":418,"leadSponsor":420,"locationsCount":421},"100585766","implementation-program-to-improve-screening-and-management-for-ckd-in-diabetes-iris-ckd-program-2-100585766","NCT06906640","Implementation pRogram to Improve Screening and Management for CKD in Diabetes (IRIS-CKD) (Program 2)","Implementation pRogram to Improve Screening and Management for CKD in Diabetes (Program 2) (IRIS-CKD)","IRIS-CKD","Inclusion Criteria:\n\n* (CKD Management)\n\n  * Adults with type 2 diabetes (T2D)\n  * Receiving primary care within the healthcare system, visit within 24 months (any PCP provider, including APP)\n  * Evidence of CKD based on laboratory testing within the past 2 years (must be confirmed during screening if not checked within 3 months of enrollment):\n\n    * UACR \\>300 mg\u002Fg or\n    * eGFR \\\u003C45 ml\u002Fmin\u002F1.73 m2 or\n    * UACR ≥30 mg\u002Fg with eGFR \\\u003C60 ml\u002Fmin\u002F1.73 m2\n  * Receiving \\\u003C100% GDMT at baseline. For patients with UACR \\\u003C30 mg\u002Fg, GDMT includes sodium-glucose cotransporter-2 inhibitors (SGLT2i) therapy. For all other eligible patients, GDMT includes ACEi\u002FARB, SGLT2i, and Finerenone, unless contraindications for any of these therapies exist (e.g., hyperkalemia, diabetic ketoacidosis, etc.).\n\nExclusion Criteria:\n\n* (CKD Management)\n\n  * Type 1 diabetes\n  * Most recent eGFR \\\u003C20 ml\u002Fmin\u002F1.73 m2\n  * Prior kidney transplant\n  * Autosomal dominant polycystic kidney disease (ADPKD)\n  * Active pregnancy or plans for conception within 1 year",{"count":401,"type":22},420,[63],"IRIS-CKD is a two-program implementation study to improve guideline-recommended screening and treatment of chronic kidney disease (CKD) in individuals with type 2 diabetes (T2D) in the United States.",[405,406,407],"Chronic Kidney Disease(CKD)","Type 2 DM","Type 2 Diabetes Mellitus (T2DM)",[409,410,411,412,413],"CKD","T2DM","T2D","Type 2 Diabetes","Chronic kidney disease","2026-06-15",{"date":336,"type":41},{"date":417,"type":41},"2025-10-28",{"date":419,"type":22},"2027-04-01",{"name":47,"class":48},7,{"id":423,"slug":424,"hasResults":12,"nctId":425,"briefTitle":426,"officialTitle":427,"acronym":398,"eligibilityCriteria":428,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":429,"targetDuration":4,"studyType":23,"phases":431,"briefSummary":432,"conditions":433,"keywords":434,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":414,"lastUpdatePostDateStruct":435,"startDateStruct":436,"completionDateStruct":437,"leadSponsor":438,"locationsCount":421},"100585765","implementation-program-to-improve-screening-and-management-for-ckd-in-diabetes-program-1-iris-ckd-100585765","NCT06906627","Implementation pRogram to Improve Screening and Management for CKD in Diabetes (Program 1) (IRIS-CKD)","Implementation pRogram to Improve Screening and Management for CKD in Diabetes (IRIS-CKD)","Screening Program-\n\nInclusion Criteria:\n\n* Adults with type 2 diabetes (T2D)\n* Receiving primary care within the healthcare system, Primary Care Provider (PCP) visit within the past 24 months (any PCP provider, including APP).\n* Lack of estimated glomerular filtration rate (eGFR) and\u002For urine albumin- creatinine ratio (UACR) measurement in the prior 15 months within the EHR\n\nExclusion Criteria:\n\n• Chronic kidney disease (CKD) diagnosis",{"count":430,"type":22},750,[63],"IRIS-CKD is an implementation study to improve guideline-recommended screening of chronic kidney disease (CKD) in individuals with type 2 diabetes (T2D) in the United States.",[405,406,407],[409,410,411,412,413],{"date":336,"type":41},{"date":417,"type":41},{"date":419,"type":22},{"name":47,"class":48},{"id":440,"slug":441,"hasResults":12,"nctId":442,"briefTitle":443,"officialTitle":444,"acronym":445,"eligibilityCriteria":446,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":447,"targetDuration":4,"studyType":23,"phases":449,"briefSummary":450,"conditions":451,"keywords":4,"overallStatus":161,"whyStopped":4,"lastUpdateSubmitDate":458,"lastUpdatePostDateStruct":459,"startDateStruct":460,"completionDateStruct":462,"leadSponsor":464,"locationsCount":465},"100642234","self-directed-mobile-mindfulness-to-address-icu-survivors-psychological-distress-100642234","NCT07634419","Self-directed Mobile Mindfulness to Address ICU Survivors' Psychological Distress","Self-directed Mobile Mindfulness to Address ICU Survivors' Psychological Distress: Lift RCT (Lift 3)","Lift 3","Inclusion Criteria:\n\nInclusion criteria present during hospitalization\n\n1. Adult (age ≥18)\n2. Managed in an ICU for ≥24 hours during the time inclusion criterion #3 is met\n3. Serious acute cardiorespiratory condition, defined as ≥1 of the following:\n\n   * mechanical ventilation via endotracheal tube for ≥4 hours\n   * non-invasive ventilation (CPAP, BiPAP) for ≥4 hours in a 24-hour period provided for acute respiratory failure\n   * new use of supplemental oxygen ≥6 liters per minute (or increase in baseline continuous oxygen)\n   * use of vasopressors for shock of any etiology\n   * use of inotropes for shock of any etiology\n   * use of pulmonary vasodilators\n   * use of aortic balloon pump or cardiac assist device for cardiogenic shock\n   * use of diuretic intravenous drip\n   * evidence of acute coronary ischemia (i.e., elevated troponin level, supporting EKG changes, unstable angina symptoms documented)\n   * urgent cardiac catheterization\n4. Cognitive status intact\n\n   o No history of pre-existing significant cognitive impairment (e.g., dementia) as per medical chart\n5. Absence of severe and\u002For persistent mental illness\n\n   o Treatment for severe and\u002For persistent mental illness (e.g., psychosis, bipolar affective disorder, schizoaffective disorder, schizoid personality disorder, schizophrenia \\[as per medical record\\], hospitalization for any psychiatric disorder) within the 6 months preceding the current hospital admission\n6. Functional fluency in English or Spanish (i.e., sufficient knowledge of English or Spanish to complete study tasks like watch videos, complete surveys)\n\nInclusion criteria present after hospital discharge (i.e., at the time of arrival home after discharge from the hospital):\n\n1\\. Elevated baseline psychological distress symptoms, defined as a PHQ-9 score ≥5\n\nExclusion Criteria:\n\nExclusion criteria present in the hospital:\n\n1\\. Discharged to a location other than a home setting (e.g., nursing home, long-term acute care facility, inpatient rehabilitation facility)\n\nExclusion criteria present after hospital discharge (i.e., at T1 Data Collection conducted at the time of arrival home from the hospital):\n\n1. Severe psychological distress as assessed by endorsement of active suicidality (see Protection of Human Subjects document for study team management of this finding)\n2. Failure to randomize within 1 month after discharge from the hospital to home\n3. Failure to login to study app and access content within 2 weeks after randomization",{"count":448,"type":22},450,[63],"Serious acute heart and lung illnesses like heart failure, severe COVID, and sepsis often leave survivors struggling not only physically, but also with lasting depression, anxiety, and stress. These problems that are hard to treat because access to mental health care is often limited. To help address this, the researchers created Lift, a fully automated mindfulness program designed with patient input and delivered through a mobile app. The investigators now plan a large, multi-site study to test whether Lift improves mental health and quality of life over six months compared to a critical illness education program called Enlighten Recovery. Overall the goal is to make an easy-to-use, widely accessible program available to people across the U.S., including those who speak Spanish.",[452,453,454,455,456,457],"Critical Illness","Heart Failure","Sepsis","Ards","Pneumonia","Trauma Injury","2026-06-12",{"date":336,"type":41},{"date":461,"type":22},"2026-06-01",{"date":463,"type":22},"2031-05-31",{"name":47,"class":48},3,{"id":467,"slug":468,"hasResults":12,"nctId":469,"briefTitle":470,"officialTitle":471,"acronym":4,"eligibilityCriteria":472,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":473,"targetDuration":4,"studyType":23,"phases":475,"briefSummary":476,"conditions":477,"keywords":479,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":483,"lastUpdatePostDateStruct":484,"startDateStruct":485,"completionDateStruct":487,"leadSponsor":489,"locationsCount":106},"100642218","cvfs-in-sih-eid-vs-pcd-ctm-100642218","NCT07582744","CVFs in SIH: EID vs. PCD CTM","CSF-Venous Fistula Detection in Spontaneous Intracranial Hypotension: Comparative Diagnostic Yields of Energy Integrating Detector Versus Photon Counting Detector CT Myelography","Inclusion Criteria:\n\n1. Adult patient,\n2. Confirmed diagnosis of SIH using International Classification of Headache Disorders criteria (third edition), and\n3. Brain MRI demonstrating at least one positive imaging finding for SIH (e.g., dural enhancement, venous sinus distention, brain sagging, pituitary engorgement, spontaneous subdural fluid collections).\n\nExclusion Criteria:\n\n1. Prior treatment of a CVF,\n2. Inability to undergo both exams (EID-CTM and PCD-CTM) if needed for diagnosis,\n3. Spine MRI demonstrating extradural CSF (confirming CSF leak type other than CVF), and\n4. inability to provide informed consent.",{"count":474,"type":22},200,[63],"The purpose of this research study is to compare two types of Computed Tomography Myelography (CTM) scans, one on the photon counting detector scanner (called PCD-CTM) and the other on the energy integrating detector scanner (called EID-CTM); both of which doctors usually use to diagnose abnormal connections between the cerebrospinal fluid and the venous system, or CSF-venous fistulas. This study will help to see if the newer PCD-CTM scan can find more spinal fluid leaks \\[CSF-venous fistulas (CVF)\\] than the scan that is normally used (EID-CTM).",[478],"Spontaneous Intracranial Hypotension",[480,481,482],"CSF-venous fistula","Photon counting detector CT myelography","Energy integrating detector myelography","2026-06-11",{"date":414,"type":41},{"date":486,"type":41},"2026-05-21",{"date":488,"type":22},"2028-08",{"name":47,"class":48},{"id":491,"slug":492,"hasResults":12,"nctId":493,"briefTitle":494,"officialTitle":495,"acronym":4,"eligibilityCriteria":496,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":497,"targetDuration":4,"studyType":23,"phases":499,"briefSummary":500,"conditions":501,"keywords":505,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":483,"lastUpdatePostDateStruct":509,"startDateStruct":510,"completionDateStruct":512,"leadSponsor":513,"locationsCount":106},"100594560","olfactory-biopsies-100594560","NCT07021040","Olfactory Biopsies","Analysis of Human Olfactory Biopsies","Group 1: Alzheimer's study\n\nInclusion Criteria:\n\n* Between the ages of 18 and 80\n* Pre-clinical AD (this cohort consists of subjects who have normal cognitive testing and function, but have positive AD biomarkers);\n* Symptomatic AD (a confirmed diagnosis of Alzheimer's or dementia who are capable of understanding and signing the consent document)\n\nExclusion Criteria:\n\n* Advanced Alzheimer's\u002Fdementia\n* Self-reported or known allergy to Afrin or Tetracain HCL (or related class of drugs)\n* Active Rhinosinusitis symptoms\n* Other known sinonasal disease history that would preclude biopsy (i.e prior sinus or skull base surgery directly impacting this anatomic region, sinonasal neoplasm in this anatomic region, olfactory cleft polyps)\n* Parkinson's disease\n* Unable or willing to complete the nasal endoscopy procedure.\n* Unable to read or speak English\n* Unable to provide legally effective consent\n\nGroup 2: Act-seq study or Non-AD controls\n\nInclusion Criteria:\n\n* Age 18 years or older\n* Patients being seen for rhinology or olfactory disorders\n* Patients having unrelated endoscopic nasal surgery\n\nExclusion Criteria:\n\n* Self-reported or known allergy to Afrin or Tetracain HCL (or related class of drugs)\n* Unable or willing to complete the nasal endoscopy procedure\n* Unable to read or speak English\n* Unable to provide legally effective consent",{"count":498,"type":22},125,[63],"This research study aims to investigate the function of the olfactory lining in the nasal cavity and its potential alterations in both healthy and diseased conditions. The olfactory lining is involved in the sense of smell.\n\nThe purpose of this study is to collect tissue from the nasal cavity.",[502,503,504],"Alzheimer Disease","Smell Loss","Smell Dysfunction",[506,507,508],"act-seq","nasal biopsy","RNA-seq",{"date":458,"type":41},{"date":511,"type":41},"2025-01-06",{"date":247,"type":22},{"name":47,"class":48},{"id":515,"slug":516,"hasResults":12,"nctId":517,"briefTitle":518,"officialTitle":519,"acronym":520,"eligibilityCriteria":521,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":522,"targetDuration":4,"studyType":23,"phases":524,"briefSummary":525,"conditions":526,"keywords":529,"overallStatus":161,"whyStopped":4,"lastUpdateSubmitDate":538,"lastUpdatePostDateStruct":539,"startDateStruct":541,"completionDateStruct":543,"leadSponsor":545,"locationsCount":4},"100643172","lifestyle-intervention-in-ckd-100643172","NCT07633145","Lifestyle Intervention In CKD","Multi-component Lifestyle Intervention to Improve Outcomes in Chronic Kidney Disease","CKD-LIFE","Inclusion Criteria:\n\n* Black race; ≥18 years old\n* history of hypertension\n* SBP ≥120 or DBP ≥80 mm Hg average of three measurements at screening visit (per KDIGO recommended SBP target of \\\u003C120 mm Hg)48\n* Stable anti-hypertensive medication regimen (i.e., no medication changes 4 weeks prior to enrollment);\n* eGFR of 15-44 ml\u002Fmin\u002F1.73m2 at screening visit\n* agreeable to randomization to either of the 2 study arms\n\nExclusion Criteria:\n\n* currently receiving or needing dialysis; having received or needing a kidney transplant\n* acute kidney injury at time of screening\n* average SBP ≥ 180 mm Hg or DBP ≥ 110 mm Hg at screening\n* Exaggerated systolic response during ETT (e.g., SBP \\>210 mmHg in men or \\>190 mmHg in women)\n* underweight (BMI \\\u003C18.5 kg\u002Fm2)\n* planned weight loss surgery in 1 year\n* a score of 27 or higher on the BP medication adherence scale\n* cardiac condition that would preclude participation in aerobic exercise training, including severe ischemic heart disease (CCS Class 3 or 4 angina or evidence of ischemia at \\\u003C85% heart rate reserve on screening treadmill testing), severe heart failure (NYHA Class 3 or 4), high grade arrhythmias, severe valvular heart disease\n* severe asthma or chronic obstructive lung disease\n* musculoskeletal or neurologic conditions that would preclude participation in aerobic exercise training\n* a major psychiatric disorder\n* illicit drug abuse\n* current alcohol consumption \\>14 drinks\u002Fweek for men and \\>7 drinks\u002Fweek for women\n* pregnant or planned pregnancy within 1 year\n* gastric bypass surgery within the last 2 years\n* a life-limiting comorbid medical condition, such as cancer.\n* physical limitation, gait instability, or need for continuous weight-bearing support that, in the opinion of study staff, would prevent safe completion of exercise treadmill testing",{"count":523,"type":22},152,[63],"This research study will test whether a 12-week healthy lifestyle program offered through a cardiac rehabilitation center can help lower blood pressure and improve kidney health in adults with advanced chronic kidney disease. Participants will be randomly assigned to either routine kidney health education or take part in a program that includes healthy eating guidance, supervised exercise sessions, and wellness coaching. The goal of the study is to determine whether this program can improve blood pressure and other factors linked to worsening kidney disease.",[527,528],"Chronic Kidney Disease","Hypertension",[530,531,532,533,534,535,536,537],"chronic kidney disease","blood pressure","lifestyle intervention","diet","exercise","weight management","cardiac rehabilitation","hypertension","2026-06-08",{"date":540,"type":41},"2026-06-10",{"date":542,"type":22},"2026-07-14",{"date":544,"type":22},"2030-06-30",{"name":47,"class":48},{"id":547,"slug":548,"hasResults":12,"nctId":549,"briefTitle":550,"officialTitle":550,"acronym":4,"eligibilityCriteria":551,"healthyVolunteers":58,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":552,"targetDuration":4,"studyType":23,"phases":554,"briefSummary":555,"conditions":556,"keywords":558,"overallStatus":161,"whyStopped":4,"lastUpdateSubmitDate":538,"lastUpdatePostDateStruct":561,"startDateStruct":562,"completionDateStruct":563,"leadSponsor":565,"locationsCount":106},"100493867","mitigating-racial-disparities-in-shared-decision-making-in-the-intensive-care-unit-100493867","NCT05710744","Mitigating Racial Disparities in Shared Decision Making in the Intensive Care Unit","Physician inclusion criterion:\n\n\\- ICU attending physician with at least 6 weeks of clinical service time in the 12 months preceding and following enrollment\n\nPhysician exclusion criterion:\n\n\\- Board certified in palliative care medicine\n\nPatient inclusion criteria:\n\n* Admitted to the ICU\n* Being treated by a study physician currently and at least for the next 48 hours\n* ≥ 18 years of age upon admission to hospital\n* Mechanically ventilated ≥ 4 days\n\nPatient exclusion criterion:\n\n* Tracheostomy tube present or decision to pursue tracheostomy within next 7 days\n* Has decision making capacity as assessed by medical team\n* Extubation planned or death anticipated in next 24 hours\n* Patients who are prisoners or are pregnant\n* Awaiting organ transplantation during this hospitalization\n* Acute respiratory failure due to progression of chronic neuromuscular disease\n* No family decision maker available\n\nFamily member inclusion criteria:\n\n* Identified by medical team as person most involved in medical decision making for the patient\n* Confirmed to be patient's legally authorized representative\n* Self-identifies as non-Hispanic, Black or White\n* ≥ 18 years of age at time of consent\n* Confirms conversational fluency in English",{"count":553,"type":22},106,[63],"This is a non randomized pilot trial aimed to:\n\nTest the feasibility of an intervention to support intensive care unit clinicians in conducting shared decision making conversations with families of patients with acute respiratory failure. The goal of this intervention is to mitigate racial disparities in shared decision making.",[557],"Health Care Disparities",[559,560],"Intensive Care Unit","Racial Disparities in Healthcare",{"date":540,"type":41},{"date":290,"type":22},{"date":564,"type":22},"2027-06-30",{"name":47,"class":48},{"id":567,"slug":568,"hasResults":12,"nctId":569,"briefTitle":570,"officialTitle":571,"acronym":4,"eligibilityCriteria":572,"healthyVolunteers":58,"sex":176,"minAge":19,"maxAge":573,"enrollmentInfo":574,"targetDuration":4,"studyType":23,"phases":576,"briefSummary":577,"conditions":578,"keywords":580,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":584,"lastUpdatePostDateStruct":585,"startDateStruct":587,"completionDateStruct":589,"leadSponsor":591,"locationsCount":106},"100636482","stress-and-menstrual-health-100636482","NCT07566260","Stress and Menstrual Health","The Influence of Non-energetic Stressors on Human Menstrual Function","Inclusion Criteria:\n\n* Adult pre-menopausal females, 18-45 years old\n* Habitually sedentary (less than 60 minutes MVPA\u002Fweek) for Exercise cohort\n\nExclusion Criteria:\n\n* Individuals on hormonal birth control (oral contraception, injection, implant, or intrauterine device)\n* Individuals with incidence in the last 6 months of childbirth, lactation, pregnancy, or functional hypothalamic amenorrhea (FHA)\n* Individuals with reproductive disorders (e.g. endometriosis, polycystic ovarian syndrome (PCOS))\n* Individuals taking thyroid medications\n* Individuals who have undergone or are undergoing menopause\n* MVPA \\>60 min\u002Fweek (for Exercise cohort)","45 Years",{"count":575,"type":22},600,[63],"The goal of this experimental study is to determine how stressors that do not directly impact energy state or energy demands (hereafter called \"non-energetic stressors\") affect reproductive health in pre-menopausal women. It aims to do this by answering the following main questions: Do non-energetic stressors create a stress response? How does the stress response impact sex hormone concentration and thus menstrual dysfunction? If stress caused by non-energetic stressors does impact sex hormone concentration, does it do so primarily at the level of the brain or the level of the ovary? Participants will be enrolled in this study for 6 months. For two of these months, they will undergo a short stress intervention and provide samples to measure hormone concentration and total energy expenditure.",[579],"Menstrual Dysfunction",[581,582,583],"Stress","Menstruation","Energy Expenditure","2026-06-04",{"date":586,"type":41},"2026-06-05",{"date":588,"type":41},"2026-05-28",{"date":590,"type":22},"2029-08",{"name":47,"class":48},{"id":593,"slug":594,"hasResults":12,"nctId":595,"briefTitle":596,"officialTitle":597,"acronym":4,"eligibilityCriteria":598,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":599,"targetDuration":4,"studyType":23,"phases":601,"briefSummary":602,"conditions":603,"keywords":605,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":584,"lastUpdatePostDateStruct":609,"startDateStruct":610,"completionDateStruct":612,"leadSponsor":614,"locationsCount":106},"100558017","sleep-sensitive-seizure-risk-assessment-with-wearable-eegs-100558017","NCT06545643","Sleep-Sensitive Seizure Risk Assessment With Wearable EEGs","Personalized Risk Assessment of Seizures Sensitive to Poor Sleep: a Longitudinal Study Using Wearable Electroencephalography Devices","Inclusion Criteria:\n\n* Age \\> 18 years\n* At least 2 seizures per week based on clinical notes\n* Patients where medications will stay stable over the study period\n* 40% of both spikes and spindles are identifiable on the dreem headband based on the screening night\n\nExclusion Criteria:\n\n* Cognitive impairment\n* Psychiatric comorbidities which may influence sleep\n* No bedpartner\u002Fcaregiver to observe seizures\n* Low agreement (below 60%) between Dreem's sleep scoring and manual scoring will be excluded from the study\n* Apnea-hypopnea index of \\> 10\u002Fh",{"count":600,"type":22},35,[63],"Epilepsy, a prevalent neurological disorder, affects 40% of patients with uncontrolled seizures despite medications. Sleep disturbance exacerbates epilepsy, and vice versa, but existing literature suffers from limitations. Studies conducted in hospital settings provide only brief observation periods and fail to capture the natural sleep environment. Wearable technology offers a promising solution, providing a nuanced understanding of the relationship between seizures and sleep. The Dreem headband, an EEG-based wearable, is well-suited for such studies, offering ease of use and validated accuracy. This technology enables extended observation periods under stable medication conditions, essential for assessing the complex interplay between sleep and epilepsy. By elucidating the impact of sleep on seizures, the researchers seek to identify patient populations where sleep significantly influences seizure susceptibility, ultimately informing personalized epilepsy treatments.",[604],"Epilepsy Intractable",[606,607,608],"epilepsy","sleep","wearable EEG",{"date":586,"type":41},{"date":611,"type":41},"2025-05-01",{"date":613,"type":22},"2028-06-01",{"name":47,"class":48},{"id":616,"slug":617,"hasResults":12,"nctId":618,"briefTitle":619,"officialTitle":620,"acronym":621,"eligibilityCriteria":622,"healthyVolunteers":58,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":623,"targetDuration":4,"studyType":23,"phases":624,"briefSummary":625,"conditions":626,"keywords":4,"overallStatus":161,"whyStopped":4,"lastUpdateSubmitDate":630,"lastUpdatePostDateStruct":631,"startDateStruct":632,"completionDateStruct":633,"leadSponsor":635,"locationsCount":106},"100581724","phase-4-notre-optimizing-long-acting-pre-exposure-prophylaxis-and-medications-for-opioid-use-disorder-interventions-in-carceral-settings-100581724","NCT06854029","NOTRE: Optimizing Long-Acting Pre-Exposure Prophylaxis and Medications for Opioid Use Disorder Interventions in Carceral Settings","Optimizing Long-Acting Pre-Exposure Prophylaxis and Medications for Opioid Use Disorder Interventions in Carceral Settings","NOTRE","Inclusion Criteria:\n\n1. Adults (age 18) at a participating carceral site;\n2. Eligible for release within 120 days (sentenced and\u002For pretrial). Individuals who might be sentenced to federal prison will be excluded;\n3. History of OUD (meeting DSM-5 criteria of moderate or severe opioid use disorder at the time of incarceration; individuals not meeting the opioid-disorder criterion will be eligible if they were treated in an opioid agonist treatment program during the year before incarceration or met OUD criteria in the year prior to incarceration);\n4. HIV negative (as confirmed by a HIV rapid test);\n5. Clinically indicated for PrEP based on CDC guidelines during incarceration and\u002For the year prior to incarceration;\n6. Willing to enroll in buprenorphine treatment and PrEP and be randomized to either study arm; and\n7. Report that, during community re-entry they will reside in the geographic locations of the study.\n\nExclusion Criteria:\n\n1. Liver function test levels greater than four times normal (if we are unable to obtain labs, a determination by our site partner physicians will be made to allow inclusion);\n2. Active medical illness that may make participation hazardous (e.g., unstable diabetes, heart disease; renal impairment, Hepatitis B);\n3. Conditions or medications that may predispose to QTc prolongation (personal or family history of long QT syndrome, hypokalemia, medications that prolong QTc interval, e.g., macrolide antibiotics, azole antifungal compounds, anti-arrhythmics, antipsychotics and antidepressants);\n4. Untreated psychiatric disorder that may make participation hazardous (e.g., untreated psychosis, treated psychiatric disorders will be allowed);\n5. Known allergic reaction to PrEP or buprenorphine; and\n6. Suicidal ideation.",{"count":448,"type":22},[25],"The investigators plan to conduct an R61\u002F33 hybrid type 2 implementation-effectiveness trial that includes 1) a one-year exploratory R61 phase that will enable the development of the intervention protocol needed for the R33 trial phase including concrete R61 phase milestones; 2) a four-year R33 phase that will include a concurrent implementation evaluation and a randomized control trial.",[627,628,629],"HIV Infections","Opioid Use Disorder","Incarceration; Lens","2026-06-03",{"date":584,"type":41},{"date":136,"type":22},{"date":634,"type":22},"2030-06-01",{"name":47,"class":48},{"id":637,"slug":638,"hasResults":12,"nctId":639,"briefTitle":640,"officialTitle":641,"acronym":4,"eligibilityCriteria":642,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":643,"targetDuration":4,"studyType":118,"phases":4,"briefSummary":644,"conditions":645,"keywords":4,"overallStatus":161,"whyStopped":4,"lastUpdateSubmitDate":647,"lastUpdatePostDateStruct":648,"startDateStruct":649,"completionDateStruct":650,"leadSponsor":652,"locationsCount":4},"100628977","sclc-tarlatamab-blood-collection-100628977","NCT07468656","SCLC Tarlatamab Blood Collection","Analysis of Blood Samples in Small Cell Lung Cancer Patients Treated With Tarlatamab","Inclusion Criteria:\n\n* Pathologically documented small cell lung cancer (SCLC) or neuroendocrine tumor\n* Appropriate candidate for treatment with tarlatamab based on investigator discretion\n* Age \\> 18 years\n* Signed written informed consent including HIPAA according to institutional guidelines\n\nExclusion Criteria:\n\n* Does not meet all inclusion criteria",{"count":7,"type":22},"The overall objective of this project is to prospectively collect blood samples throughout treatment with tarlatamab in patients with small cell lung cancer (SCLC). These samples will then be analyzed through a variety of assays to better characterize tarlatamab in the real-world setting.\n\nThe investigators will prospectively collect blood samples from 25 patients on days 1, 8, and 15 of tarlatamab treatment, as well as after each interval scan for disease monitoring. The investigators will also collect patient data including demographics and baseline characteristics, primary diagnosis, treatment history, and disease monitoring and progression.",[646],"Small-cell Lung Cancer","2026-06-02",{"date":630,"type":41},{"date":218,"type":22},{"date":651,"type":22},"2028-12",{"name":47,"class":48},""]